Industry News (Patents and Technologies)

U.S. Patent Received for BEC-2 Cancer Vaccine

Published in Vaccine Weekly, August 5th, 1996

ImClone Systems Inc., New York, New York, announced that the U.S. Patent and Trademark Office (PTO) has issued U.S. Patent No. 5,529,922 for the therapeutic vaccine, BEC-2.

BEC-2 is a proprietary anti-idiotypic monoclonal antibody designed to mimic GD3, a glycolipid (ganglioside) antigen which is found on the surface of a number of tumor cells, including small cell lung cancer (SCLC), melanoma and a variety of soft tissue sarcomas, and is intended to elicit a cancer-fighting immune response in patients with these tumor cells. BEC-2 works by inducing an immune response against the GD3 ganglioside.

On May 20, 1996, at the Annual Meeting of the 32nd...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1996-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry